Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Large Decrease in Short Interest

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 78,900 shares, a drop of 23.6% from the November 15th total of 103,300 shares. Based on an average daily trading volume, of 2,830,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 2.9% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Maxim Group dropped their price target on Theriva Biologics from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th.

Theriva Biologics Price Performance

TOVX traded down $0.01 during midday trading on Friday, hitting $1.18. The stock had a trading volume of 50,433 shares, compared to its average volume of 928,365. Theriva Biologics has a 1 year low of $1.14 and a 1 year high of $17.11. The firm has a market cap of $3.28 million, a P/E ratio of -0.04 and a beta of 1.33.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($6.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.25) by ($0.56).

Institutional Trading of Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP bought a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned 6.13% of Theriva Biologics as of its most recent SEC filing. Hedge funds and other institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.